--- title: "NuCana (NCNA) news: offering" url: "https://aibio.space/companies/nucana/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NCNA offering news: NuCana plc prices best-efforts offering of 2,452,935 ADSs with warrants. NuCana plc (NASDAQ: NCNA), United Kingdom." --- NCNA NuCana plc NASDAQ · United Kingdom # NuCana (NCNA) news NCNA offering news Financings · 2026-03-19 ## [NuCana says £24.3 million in cash should fund operations into 2029](https://aibio.space/news/nucana-says-24-3-million-cash-should-fund-operations-2029/) NuCana's cash rose to £24.3 million after two 2025 raises, but its 2025 net loss was £29.4 million and net cash used in operating activities was £7,467 thousand. The melanoma data for NUC-7738 come from an expansion study the release does not size. ## Latest NuCana news 1. 2025-09-05 Listings [NuCana says Nasdaq confirmed compliance and closed its listing matter](https://aibio.space/news/nucana-says-nasdaq-confirmed-compliance-closed-listing-matter/) The company says Nasdaq closed its listing matter and that its cash lasts into 2029. The release gives no cash balance or burn figure and does not say what steps restored compliance. 2. 2025-05-07 Financings [NuCana plc prices best-efforts offering of 2,452,935 ADSs with warrants](https://aibio.space/news/nucana-plc-prices-best-efforts-offering-2-452-935-adss-warrants/) The combined price of $0.6454 per ADS is set below the $1.10 last sale price on May 5, 2025. Warrant terms and a zero exercise price option on the Series B warrants could issue far more ADSs than the 2,452,935 sold. 3. 2025-04-24 Financings [NuCana files for offering of up to 16,049,383 ADSs with Series A and B warrants](https://aibio.space/news/nucana-files-offering-up-16-049-383-adss-series-b-warrants/) The offering is a best-efforts deal placed by Laidlaw & Company (UK) Ltd. Warrant terms with a zero exercise price option and reset provisions could push the number of ADSs issued far above the 16,049,383 offered. ## NuCana at a glance - **Ticker**: NCNA - **Listing**: NASDAQ - **Country**: United Kingdom ### Related companies - [Oxford BioDynamics Plc](https://aibio.space/companies/oxford-biodynamics/) LSE: OBD - [Adaptimmune Therapeutics](https://aibio.space/companies/adaptimmune-therapeutics/) OTC: ADAPY - [Genflow Biosciences Plc](https://aibio.space/companies/genflow-biosciences/) LSE: GENF - [Thalia Therapeutics](https://aibio.space/companies/thalia-therapeutics/) LSE: THAT - [Bioventix Plc](https://aibio.space/companies/bioventix/) LSE: BVXP - [HemoGenyx Pharmaceuticals Plc](https://aibio.space/companies/hemogenyx-pharmaceuticals/) LSE: HEMO - [COMPASS Pathways Plc](https://aibio.space/companies/compass-pathways/) NASDAQ: CMPS - [Scancell Holdings Plc](https://aibio.space/companies/scancell/) LSE: SCLP ### Also on NASDAQ - [Enanta Pharmaceuticals](https://aibio.space/companies/enanta-pharmaceuticals/) ENTA - [TransMedics Group](https://aibio.space/companies/transmedics/) TMDX - [Intellia Therapeutics](https://aibio.space/companies/intellia-therapeutics/) NTLA - [Iovance Biotherapeutics](https://aibio.space/companies/iovance-biotherapeutics/) IOVA - [Latigo Biotherapeutics](https://aibio.space/companies/latigo-biotherapeutics/) LTGO - [Greenwich LifeSciences](https://aibio.space/companies/greenwich-lifesciences/) GLSI ## Questions about NuCana Has NuCana raised money recently? Our latest story on this, dated May 7, 2025: "NuCana plc prices best-efforts offering of 2,452,935 ADSs with warrants". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nucana-plc-prices-best-efforts-offering-2-452-935-adss-warrants/). What is the ticker symbol of NuCana? NuCana plc trades under the ticker NCNA on NASDAQ. Where is NuCana listed? NuCana plc is listed on NASDAQ. What is the SEC CIK of NuCana? The SEC Central Index Key (CIK) for NuCana plc is 1709626. Its filings are on SEC EDGAR. How many shares does NuCana have outstanding? 20,809,854,947 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-19. Which country or territory is NuCana listed under? Our directory records NuCana plc under United Kingdom. What does NuCana do? Our directory classifies NuCana plc as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of NuCana? The ISIN recorded for NuCana plc is US67022C3043. Does aibio.space cover NuCana? aibio.space lists NuCana plc among 2,820 public biotech companies and publishes its news here as stories appear. Where is NuCana incorporated? SEC records list its state or country of incorporation as X0. What is the latest NuCana (NCNA) stock news? Our latest story on NuCana, dated Mar 19, 2026: "NuCana says £24.3 million in cash should fund operations into 2029". NuCana's cash rose to £24.3 million after two 2025 raises, but its 2025 net loss was £29.4 million and net cash used in operating activities was £7,467 thousand. The melanoma data for NUC-7738 come from an expansion study the release does not size. [Source](https://aibio.space/news/nucana-says-24-3-million-cash-should-fund-operations-2029/). How long will NuCana's cash last? From our story of Mar 19, 2026: The company expects that cash to fund operations into 2029. [Source](https://aibio.space/news/nucana-says-24-3-million-cash-should-fund-operations-2029/). Is NuCana at risk of delisting? Our latest listing story, dated Sep 5, 2025: "NuCana says Nasdaq confirmed compliance and closed its listing matter". The company says Nasdaq closed its listing matter and that its cash lasts into 2029. The release gives no cash balance or burn figure and does not say what steps restored compliance. [Source](https://aibio.space/news/nucana-says-nasdaq-confirmed-compliance-closed-listing-matter/). Is NuCana a smaller reporting company? SEC records list NuCana plc's filer category as: Non-accelerated filer. Where is NuCana headquartered? SEC records list its business address as 3 LOCHSIDE WAY, EDINBURGH, United Kingdom, EH12 9DT. ## Investor discussion: NuCana Members talk about NuCana (NCNA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at NuCana, newest first. Each line links the filing it comes from. 1. 2026-03-19 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1709626/000119312526115968/d114647dex991.htm) 2. 2025-09-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1709626/000119312525196589/d43041dex991.htm) 3. 2025-08-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1709626/000119312525171672/d946524dex991.htm) 4. 2025-07-21 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1709626/000119312525161557/d11110dex991.htm) 5. 2025-07-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1709626/000119312525156987/d67466d6k.htm) 6. 2025-06-27 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1709626/000119312525151430/d904456d6k.htm) 7. 2025-06-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1709626/000119312525142535/d946009d6k.htm) 8. 2025-05-07 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1709626/000119312525114453/d906809d424b4.htm) 9. 2025-04-24 Financings Filed a registration statement for a share offering. SEC Form F-1. [Source](https://www.sec.gov/Archives/edgar/data/1709626/000119312525092131/d906809df1.htm) 10. 2025-03-20 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1709626/000119312525059014/d266089dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NCNA on TradingView](https://www.tradingview.com/symbols/NASDAQ-NCNA/). ## SEC filings and registration - **SEC name**: NuCana plc - **CIK**: 1709626 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NCNA (Nasdaq) - **State or country of incorporation**: X0 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: 3 LOCHSIDE WAY, EDINBURGH, United Kingdom, EH12 9DT - **Phone**: 44-0-131-357-1111 - **Shares outstanding**: 20,809,854,947 as of 2025-12-31 (20-F filed 2026-03-19) - **Former names**: NuCana BioMed Ltd ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1709626/000119312526408365/d285861d6k.htm) filed 2026-09-30 - [6-K](https://www.sec.gov/Archives/edgar/data/1709626/000119312526349254/d140331d6k.htm) filed 2026-08-13 - [6-K](https://www.sec.gov/Archives/edgar/data/1709626/000119312526260703/d28471d6k.htm) filed 2026-06-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1709626/000119312526249817/d247626d6k.htm) filed 2026-06-01 - [6-K](https://www.sec.gov/Archives/edgar/data/1709626/000119312526224224/d96757d6k.htm) filed 2026-05-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1709626/000119312526208951/d118567d6k.htm) filed 2026-05-06 - [20-F](https://www.sec.gov/Archives/edgar/data/1709626/000119312526116030/ncna-20251231.htm) filed 2026-03-19 - [6-K](https://www.sec.gov/Archives/edgar/data/1709626/000119312526115968/d114647d6k.htm) filed 2026-03-19 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001709626), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details NuCana plc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NCNA, recorded under United Kingdom. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: NuCana plc - **Ticker**: NCNA - **Listing**: NASDAQ - **Country or territory**: United Kingdom - **Business scope**: Biotechnology - **ISIN**: US67022C3043 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NCNA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nucana/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "NuCana (NCNA) news: offering", 2026-10-31, https://aibio.space/companies/nucana/